发明名称 Kanag liflozin
摘要 Use of a compound of formula (IA): wherein R A is a halogen atom, a lower alkyl group or a lower alkoxy group; R B is a phenyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, or a mono- or di-lower alkylamino group; or a heterocyclyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, or a mono- or di-lower alkylamino group; and R c is hydrogen atom; or R B and R C taken together are a fused benzene ring which may be substituted by a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group or a halo-lower alkoxy group; in combination with another antidiabetic agent, an anti-obesity agent, an antihypertensive agent, an antiplatelet agent, an anti-atherosclerotic agent and/or a hypolipidemic agent, in the manufacture of a medicament for the treatment of diabetes mellitus (type 1 and type 2), diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, postprandial hyperglycemia, or delayed wound healing.
申请公布号 NO2014009(I1) 申请公布日期 2014.06.02
申请号 NO20140000009C 申请日期 2014.04.25
申请人 MITSUBISHI TANABE PHARMA CORP 发明人
分类号 A61K31/7072;C07H19/048;C07H19/06 主分类号 A61K31/7072
代理机构 代理人
主权项
地址